Results 101 to 110 of about 50,416 (260)

"STATINS KALEIDOSCOPE". MYOPATHY FROM STATINS [PDF]

open access: yes, 2019
Statins are medications that inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme, thus inhibiting cholesterol biosynthesis. Statins reduce cardiovascular risk and morbidity in patients with coronaropathia, however, without forgetting their side ...
NUHAJ, LEDIANA   +4 more
core   +1 more source

Statins—From Fungi to Pharmacy

open access: yes, 2023
Statins have been used in the treatment of hyperlipidemia, both as monotherapy and in combination therapy. Natural fermentation processes of fungi such as Monascus spp., Penicillium spp., Aspergillus terreus, and Pleurotus ostreatus have given rise to ...
Alicja Roztocka   +6 more
core   +1 more source

Longitudinal Echocardiographic Surveillance of Aortic Dilation in a Phenotype‐Enriched Turner Syndrome Cohort

open access: yesAmerican Journal of Medical Genetics Part A, EarlyView.
ABSTRACT Turner syndrome (TS) is associated with thoracic aortopathy and increased risk for aortic dissection, yet the natural history of aortic dilation is not well understood. We performed a retrospective longitudinal study of individuals with TS who participated in the TS Society of the United States Healthy Heart Project between 2003 and 2023 ...
Dylan Doerner   +7 more
wiley   +1 more source

Statins [PDF]

open access: yesVascular Medicine, 2017
Elizabeth V, Ratchford, Seth S, Martin
openaire   +2 more sources

Outcomes in Progressive Pulmonary Fibrosis in Systemic Autoimmune Rheumatic Diseases: Real‐World Data From the ILD‐PRO Registry

open access: yesArthritis &Rheumatology, EarlyView.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease–associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J. Bracken   +7 more
wiley   +1 more source

Genome-wide study of gene variants associated with differential cardiovascular event reduction by Pravastatin therapy [PDF]

open access: yes, 2012
Statin therapy reduces the risk of coronary heart disease (CHD), however, the person-to-person variability in response to statin therapy is not well understood.
Westendorp, Rudi G. J.   +88 more
core   +2 more sources

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló   +5 more
wiley   +1 more source

Nonadherence and uncontrolled arterial hypertension in Croatia—Insights from the May Measurement Month 2023 campaign and Hunting the silent killer programme

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims To determine the prevalence of non‐adherence to antihypertensive medicines and to identify demographic and behavioral factors associated with non‐adherence in subjects enrolled in the May Measurement Month (MMM) 2023, as part of the permanent public health action Hunting the silent killer.
Valerija Bralić Lang   +12 more
wiley   +1 more source

Drug interactions with statins [PDF]

open access: yes, 2013
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are generally very well tolerated as monotherapy. Statins are associated with two important, adverse effects, asymptomatic elevation in liver enzymes and myopathy ...
Anida Causevic-Ramosevac   +3 more
core   +1 more source

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy